GLP-1 drugs “alter taste perception” and "disrupt the perception of sweetness, bitterness, fatty foods and even mouthfeel”, a ...

GLP-1 meds may help — or harm — those with bipolar disorder. Read firsthand accounts of mood changes, weight loss, and side ...

GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, ...

For patients with diabetes, exposure to GLP-1 RAs is associated with an increased risk for incident neovascular AMD development.

After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Ozempic, which was introduced into the UK in January 2019, having previously been approved in the US in 2017, is an ...